

# Resource Summary Report

Generated by ASWG on Aug 10, 2026

## Recombinant Anti-Bcl6 antibody [EPR11410-43]

RRID:AB\_2924917

Type: Antibody

### Proper Citation

Abcam Cat# ab172610, RRID:AB\_2924917

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2924917](http://antibodyregistry.org/AB_2924917)

**Proper Citation:** Abcam Cat# ab172610, RRID:AB\_2924917

**Target Antigen:** Bcl6

**Host Organism:** rabbit

**Clonality:** recombinant monoclonal

**Comments:** Applications: WB, IHC-P

**Antibody Name:** Recombinant Anti-Bcl6 antibody [EPR11410-43]

**Description:** This recombinant monoclonal targets Bcl6

**Target Organism:** human

**Clone ID:** EPR11410-43

**Antibody ID:** AB\_2924917

**Vendor:** Abcam

**Catalog Number:** ab172610

**Record Creation Time:** 20250820T010502+0000

**Record Last Update:** 20250820T095901+0000

### Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-Bcl6 antibody [EPR11410-43].

No alerts have been found for Recombinant Anti-Bcl6 antibody [EPR11410-43].

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 5 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [ASWG](#) .

Kirschstein E, et al. (2026) Myofibroblast programming blocks differentiation of TLS-organizing fibroblastic reticular cells in pancreatic cancer. *Cancer cell*, 44(5), 1080.

Liang X, et al. (2025) Limited activation interdependence and differing patterns of the in vivo effects of IKK1 and IKK2 downstream of NIK. *Cell reports*, 44(10), 116404.

Abe Y, et al. (2025) Distinct follicular T cell subsets regulate lymphoma progression and outcomes. *Cancer cell*.

Zhang Y, et al. (2024) CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis. *Cancer cell*, 42(8), 1370.

Ma X, et al. (2023) Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN- $\gamma$  axis. *Cell reports*, 42(8), 112944.